2
Participants
Start Date
February 28, 2018
Primary Completion Date
July 24, 2018
Study Completion Date
July 24, 2018
Genetically engineered T Cell Receptors
No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Sarah Cannon Research Institute, Nashville
University of Texas MD Anderson Cancer Center, Houston
Princess Margaret Cancer Centr, Toronto
Lead Sponsor
Adaptimmune
INDUSTRY